Hong Kong, September 28th / PRNewswire / —— Regent Pacific Group Limited (“Regent Pacific” or “the Company”, collectively referred to as “the Group” together with its subsidiaries; stock code: 0575. HK ) announced that its AI-owned subsidiary Deep Longevity, which specializes in intelligent solutions for biological aging, will launch a consumer digital health and telemedicine platform Accrua ™ (“Accrua”) in the United States in October 2026. Once launched, the platform will be available to consumers in all 50 states of the United States, providing personalized, doctor-guided care based on users’ biological age rather than just symptoms.
Accrua is an important step in Deep Longevity's strategy to target consumers directly in the US market ( D2C ), and it complements the group's existing business-to-business ( B2B ) collaborations with clinics, hospitals, laboratories, and insurance companies. The company states that this is also the first time Deep Longevity's proprietary and award-winning aging clock technology and the SenoClock ® platform have been made directly available to consumers. The board of directors believes that this will become an important new source of revenue for the group in the future.
About Accrua
Accrua provides online medical services led by licensed clinical doctors in the United States, with a simple and direct process. At the core of the platform is Deep Longevity's independently developed AI, which generates BloodAge reports. These reports use routine blood tests to determine whether consumers belong to the category of "people who age faster" – that is, those whose biological age increases more rapidly than their actual age.
After completing consultations with clinicians, Accrua provides a range of treatment options under the guidance of doctors, including weight loss medications (such as glucagon-like peptide-1, commonly referred to as GLP-1 therapy), peptides, women's health treatments (such as hormone replacement therapy), and men's health treatments (such as testosterone therapy). Each treatment plan is individually tailored by licensed clinicians and is based on the user's BloodAge reports, rather than solely on self-reported symptoms or a single biomarker; BloodAge will be re-measured quarterly so that users and their clinicians can track progress based on objective and scientific indicators of biological aging.
Accrua is built around the premise that "you know your age, but your blood knows you better." It integrates quarterly biological age measurements, clinician-guided treatment, and compound therapies into a comprehensive longevity care program, supported by peer-reviewed scientific research. The BloodAge model of Deep Longevity was the subject of peer-reviewed studies (such as Goshen, Aging, and, Disease, 2026); these studies followed approximately 2,600 adults for an average of 9.2 years and found that for each additional year of discrepancy between biological age and actual age, the risk of death increased by 15%. The technology of Deep Longevity also recently won second place in the Nestl é VITAL Smart Aging Global Challenge; this is a global innovation competition that attracted entries from 150 companies.
A vast and rapidly growing market
Accrua is entering the US consumer digital health market, where platforms in related segments have already achieved considerable revenue. The US digital telemedicine platform MEDVi, which focuses on GLP-1 weight loss and related therapies, LLC generated over $400 million in revenue in 2025, which was its first full year of operation; according to a report by The New York Times on April 2, 2026, and cited by Forbes on the same day, the company's annualized revenue in 2026 was approximately $1.8 billion. Although it cannot be guaranteed that Accrua will achieve similar results, the board of directors believes that these figures illustrate the scale of consumer demand as well as the revenue potential of the market that Accrua targets.
Capital-efficient and scalable business model
The design of Accrua adopts a model that is highly capital-efficient and scalable. Clinical services will be provided through established partners in the field of telemedicine in the United States, as well as a network composed of independently licensed doctors, pharmacies, and compounding partners. This network will cover all 50 states of the US, handling consultation, prescription issuance, pharmacy fulfillment, patient access, and billing processes. As a result, Deep Longevity does not need to build its own clinical infrastructure or directly hold inventory of medications, allowing it to expand nationwide from the moment it goes live. The company states that this approach will maintain operational flexibility while minimizing the upfront capital investment required for expansion. Revenue is expected to come primarily from subscriptions and will have a recurring nature. The platform will operate on infrastructure that meets the requirements of HIPAA and will obtain LegitScript certification before launch. This launch will be accompanied by targeted digital marketing efforts, initially focusing on certain states in the US, in order to optimize customer acquisition before further expansion.
The Executive Director and Chief Executive Officer, Jamie Gibson, stated: "The launch of Accrua is a milestone for both Deep Longevity and the entire group. For the first time, American consumers can directly access our BloodAge science, and personalized care is provided by licensed clinicians. We believe that anchoring treatment based on biological age, rather than just symptoms, is a truly novel approach, and the market has already shown exceptionally strong consumer demand. We are excited about the opportunities ahead."
About Deep Longevity
Deep Longevity is a biogerontology intelligence company driven by AI, dedicated to making healthy aging measurable and actionable. Its proprietary aging clock technology has been scientifically verified through peer-reviewed studies and published in several leading international journals. This technology can measure biological and cognitive aging in multiple physiological systems, enabling medical and consumer health organizations to integrate personalized aging intelligence into their products and services. For more information, please visit www.deeplongevity.com.
Regarding Regent Pacific Group Limited (Stock Code: 0575. HK)
Regent Pacific is a diversified investment group headquartered in Hong Kong, currently holding multiple enterprises and strategic investments, with a focus on the healthcare, wellness, and life sciences sectors. Since its initial public offering in May 1997, the group has had a good track record in investing and has returned approximately $298 million to its shareholders.
In case of any discrepancies or inconsistencies between the English version and the Chinese translation, the English version shall prevail.
